Literature DB >> 6800251

Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm.

J A Hill, R L Feldman, C J Pepine, C R Conti.   

Abstract

The effects of nifedinpine and isosorbide dinitrate on the frequency of angina and consumption of nitroglycerin were studied in 19 patients with coronary arterial spasm. After a lead-in phase, the patients were randomized to treatment with either nifedipine or isosorbide dinitrate. After dose titration (40 to 120 mg/day) and evaluation, they were given the alternate therapy. During the initial segment of the double-blind phase, one patient died suddenly (nifedipine phase), one dropped out of the study (nifedipine phase) and another was unable to tolerate therapy (isosorbide dinitrate phase). In the other 16 patients, the mean frequency of angina was less during therapy with both nifedipine (0.69 episode/day, p less than 0.05) and isosorbide dinitrate (0.77 episode/day, p less than 0.05) phases than during the lead-in phase (1.71 episodes/day). The mean frequency of angina was similar in the nifedipine and isosorbide dinitrate phases. A 50 percent or greater decrease in frequency of angina compared with lead-in phase values occurred in 13 of 18 patients during treatment with nifedipine and in 10 of 16 during treatment with isosorbide dinitrate. Of the 16 patients who completed both double-blind phases, 7 showed greater improvement (that is, a 50 percent or greater decrease in frequency of angina) with nifedipine than with isosorbide dinitrate); 6 others showed greater improvement with isosorbide dinitrate, and the other 3 had a less than 50 percent difference in frequency of angina with the two drugs. These findings in a limited number of patients suggest that both nifedipine and isosorbide dinitrate are effective in certain patients with coronary spasm but that neither drug is clearly superior.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800251     DOI: 10.1016/0002-9149(82)90521-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Coronary Artery Spasm.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

Review 2.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Eur Cardiol       Date:  2018-08

5.  Long acting nifedipine in the treatment of severe hypertension.

Authors:  M Bursztyn; E Grossmann; T Rosenthal
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Prevention of vasospastic angina with nicardipine.

Authors:  C J Pepine; J S Gelman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 7.  Use of nitrates in the treatment of unstable and variant angina.

Authors:  R Nordlander
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 9.  Calcium antagonists. Clinical use in the treatment of angina.

Authors:  P Théroux; Y Taeymans; D D Waters
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 10.  Vasodilator Therapy: Nitrates and Nicorandil.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Cardiovasc Drugs Ther       Date:  2016-08       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.